NDA 022395 · Averitas
Qutenza
Capsaicin · Topical
NovelOrphanLast checked: Nov 20, 2026Latest source record: Jul 31, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Nov 16, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
185
31 Phase 3, 12 recruiting
FAERS reports
3,257
1,865 serious, 156 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 7, 2026.
QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. QUTENZA is a TRPV1 channel agonist indicated for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. ( 1 )
Mechanism: Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations. This is followed by pain relief thought to be mediated by a reduction in TRPV1-expressing nociceptive nerve endings [see Clinical Pharmacology ( 12.2 )] . Over the course of several months, there may be a gradual re-emergence of painful neuropathy...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 17, 2020 Supplement 19 · Efficacy LetterLabel
- Nov 16, 2009 Original approval · Type 1 - New Molecular Entity NovelOrphanSummary ReviewLabelReview
1 products under this application
- QUTENZA · CAPSAICIN 8% · PATCH, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Capsaicin" as an intervention, any sponsor and status, largest first.
- An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OAPivotal-lookingCompleted
Centrexion TherapeuticsIndustry
NCT03661996 · 854 participants · Start Sep 18, 2018 · Primary completion Oct 22, 2019
Drug: CNTX-4975-05; Lidocaine without epinephrine · For: Knee Osteoarthritis
Sites: Birmingham, Alabama; Peoria, Arizona; Tucson, Arizona · 28 sites in all
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes ZosterPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07361796 · 832 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 30, 2027
Drug: Venlafaxine combined conventional therapy; Conventional therapy · For: Herpes Zoster; Pain; Postherpetic Neuralgia
Sites: Beijing, China
- Capsaicin + Diclofenac Gel in Acute Back Pain or Neck PainPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02700815 · 746 participants · Start May 9, 2016 · Primary completion Jul 13, 2017
Drug: Diclofenac; Capsaicin and 1 more · For: Acute Pain
Sites: Berlin, Germany; Bochum, Germany; Cologne, Germany · 18 sites in all
- Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPivotal-lookingNot yet recruiting
University of MichiganAcademic, hospital or other
NCT07795593 · 600 participants (planned) · Start Nov 2026 · Primary completion May 2031
Drug: Oral Medication; Topical Medication · For: Painful Diabetic Neuropathy (PDN); Diabetic Nephropathies
Sites: Stanford, California; Jacksonville, Florida; Chicago, Illinois · 23 sites in all
- A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of TreatmentPivotal-lookingCompleted
Astellas Pharma Europe Ltd.Astellas (ALPMY)
NCT01713426 · 568 participants · Start Jul 11, 2012 · Primary completion Sep 26, 2013
Drug: Qutenza; Pregabalin · For: Non-diabetic Painful Peripheral Polyneuropathy; Postherpetic Neuralgia (PHN); Peripheral Nerve Injury (PNI)
Sites: Yerevan, Armenia; Klagenfurt, Austria; Innsbruck, Austria · 98 sites in all
- Study of NGX-4010 for the Treatment of Painful HIV-Associated NeuropathyPivotal-lookingCompleted
NeurogesXIndustry
NCT00321672 · 494 participants · Start Jun 2006 · Primary completion Dec 2007
Drug: NGX-4010, 8% capsaicin patch; 0.04% capsaicin patch and 2 more · For: Pain; HIV Infections; Peripheral Nervous System Diseases
- A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic PatientsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01478607 · 468 participants · Start Nov 2011 · Primary completion Feb 2014
Drug: QUTENZA · For: Painful Diabetic Peripheral Neuropathy (PDPN)
Sites: Bonheiden, Belgium; Beroun, Czechia; Brno, Czechia · 64 sites in all
- Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After SurgeryPivotal-lookingCompleted
Averitas Pharma, Inc.Industry
NCT04967664 · 412 participants · Start Jul 13, 2021 · Primary completion Aug 28, 2025
Drug: Qutenza (capsaicin) 8% topical system; capsaicin 0.04% topical system · For: Post Surgical Neuropathic Pain
Sites: Tucson, Arizona; Vista, California; Washington D.C., District of Columbia · 64 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- application site pain607
- pain424
- drug ineffective377
- burning sensation330
- pain in extremity215
- application site erythema165
- fatigue159
- off label use145
- insomnia110
- dyspnoea105
- paraesthesia100
- weight increased100
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 24 |
| 2006 | 21 |
| 2007 | 23 |
| 2008 | 6 |
| 2009 | 13 |
| 2010 | 17 |
| 2011 | 44 |
| 2012 | 86 |
| 2013 | 78 |
| 2014 | 117 |
| 2015 | 105 |
| 2016 | 133 |
| 2017 | 114 |
| 2018 | 137 |
| 2019 | 173 |
| 2020 | 130 |
| 2021 | 183 |
| 2022 | 197 |
| 2023 | 250 |
| 2024 | 326 |
| 2025 | 724 |
| 2026 | 340 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Qutenza (Capsaicin/Skin Cleanser)
2024 spending
$21.3M
Beneficiaries
3,782
6,290 claims
Per beneficiary
$5,645
$3,018.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $730,180 |
| 2021 | $1,979,006 |
| 2022 | $4,952,531 |
| 2023 | $12,460,288 |
| 2024 | $21,347,581 |
Part B: Qutenza (Capsaicin/Skin Cleanser) · HCPCS J7336
2024 spending
$29.5M
Beneficiaries
5,271
9,155 claims
Per beneficiary
$5,603
2024 ASP limit $3.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $238,861 |
| 2021 | $2,275,396 |
| 2022 | $11,137,495 |
| 2023 | $22,106,184 |
| 2024 | $29,534,286 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.
Finnerup NB, Attal N, Haroutounian S, et al. · Lancet Neurol 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis.
Soliman N, Moisset X, Ferraro MC, et al. · Lancet Neurol 2025 · Systematic Review, Meta-Analysis
- Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study.
Simpson DM, Robinson-Papp J, Van J, et al. · J Pain 2017 · Clinical Trial, Phase III, Multicenter Study
- [Pharmacological management of neuropathic pain].
Bouchenaki H, Bégou M, Magy L, et al. · Therapie 2019 · Meta-Analysis, Systematic Review
- Cough reduction using capsaicin.
Ternesten-Hasséus E, Johansson EL, Millqvist E · Respir Med 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Capsaicin for non-allergic rhinitis.
Gevorgyan A, Segboer C, Gorissen R, et al. · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Averitas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.